• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:许爱笑,邵雪晶,应美丹,杨波.抗肿瘤药物的基础与转化研究助推临床治疗[J].中国现代应用药学,2023,40(12):1658-1661.
XU Aixiao,SHAO Xuejing,YING Meidan,YANG Bo.Basic and Translational Research on Antitumor Drugs Promotes Clinical Therapy[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(12):1658-1661.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 3814次   下载 576 本文二维码信息
码上扫一扫!
分享到: 微信 更多
抗肿瘤药物的基础与转化研究助推临床治疗
许爱笑, 邵雪晶, 应美丹, 杨波
浙江大学药学院, 浙江省抗肿瘤药物临床前研究重点实验室, 杭州 310058
摘要:
恶性肿瘤已成为严重威胁人类健康的主要公共卫生问题之一。随着医药科技的发展,肿瘤患者的生存率有了明显提升。但是,现有治疗策略远远无法满足临床需求,目前仍存在可用药物少、不良反应严重等问题。为进一步推进肿瘤患者的临床治疗,本期推出了“抗肿瘤药物研究与转化”专栏,分别从“抗肿瘤药物靶点及先导化合物发现”及“抗肿瘤药物的智能递送转化研究”两大主题开展深入探讨,以期为肿瘤患者的临床治疗提供药物新靶点和治疗新策略,助推抗肿瘤创新药物的研发。
关键词:  抗肿瘤药物  药物靶点  先导化合物  智能递送
DOI:10.13748/j.cnki.issn1007-7693.20231449
分类号:R96
基金项目:
Basic and Translational Research on Antitumor Drugs Promotes Clinical Therapy
XU Aixiao, SHAO Xuejing, YING Meidan, YANG Bo
College of Pharmaceutical Sciences, Zhejiang University, Zhejiang Province Key Laboratory of Anti-cancer Drug Research, Hangzhou 310058, China
Abstract:
Malignant tumors have emerged as a significant public health problem, posing a grave threat to the human health. With the development of medical technology, the survival rate of tumor patients has shown remarkable improvement. However, the existing treatment strategies are far from meeting the clinical needs, and problems are still existed such as few available drugs and serious adverse reactions. To further advance the clinical treatment of tumor patients, this issue presents the column of “Antitumor Drug Research and Translation”, which is divided into two major topics, “the discovery of antitumor drug target and lead compound” and “intelligent delivery of antitumor drugs for translation research”. This column aims to provide novel drug targets and therapeutic strategies for the clinical treatment of tumor patients, thereby boosting the development of innovative anti-tumor drugs.
Key words:  antitumor drug  drug target  lead compound  intelligent delivery
扫一扫关注本刊微信